SK Pharmteco

12460 Akron Street, Suite 100
95742 Rancho Cordova, CA
US

Contact WebSite

SK Pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the US, Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK Pharmteco is a subsidiary of SK Inc., the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

Article

28.10.2025 • News • Pharma

SK Pharmteco Invests $6.1 Million in Peptide Manufacturing at California Facility

SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.

03.10.2024 • News • Pharma

SK Pharmteco to Expand Production in South Korea

South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.

24.07.2023 • News • Pharma

SK Biopharmaceuticals Aims to Become 'Big Biotech'

SK Biopharmaceuticals, a South Korean-based biotech, has announced its new strategy to propel the company towards becoming a global “big biotech.”

17.06.2022 • News

Expansion at SK Biotek API Plant to Cost $35 Miilion

South Korean CDMO SK Pharmteco (SKTP) said it will spend $35 million on the initial phase of a planned expansion at the Dublin, Ireland, API site the conglomerate acquired from Bristol Myers Squibb in 2017. Prior to that, SK had been a BMS supplier for around a decade.